The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

导出原文传递

翻译打印收藏纠错

作者： Hiromi,Watanabe ^[1] ; Toshio,Kubo ^[2] ; Kiichiro,Ninomiya ^[1] ; Kenichiro,Kudo ^[3] ; Daisuke,Minami ^[4] ; Etsuko,Murakami ^[5] ; Nobuaki,Ochi ^[6] ; Takashi,Ninomiya ^[1] ; Daijiro,Harada ^[7] ; Masayuki,Yasugi ^[8] ; Eiki,Ichihara ^[9] ; Kadoaki,Ohashi ^[1] ; Keiichi,Fujiwara ^[1] ; Katsuyuki,Hotta ^[4] ; Masahiro,Tabata ^[1] ; Yoshinobu,Maeda ^[10] ; Katsuyuki,Kiura ^[2]

作者单位： Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan. ^[1] Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan. ^[2] Respiratory Medicine, Iwakuni Medical Center, Iwakuni, Japan. ^[3] Respiratory Medicine, Okayama Medical Center, Okayama, Japan. ^[4] Respiratory Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan. ^[5] General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan. ^[6] Health Service Center, Okayama University, Okayama, Japan. ^[7] Respiratory Medicine, Shikoku Cancer Center, Matsuyama, Japan. ^[8] Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan. ^[9] Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan. ^[10] Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. ^[11]

关键词 immune checkpoint inhibitor non-small cell lung cancer rechallenge